RRAD suppresses the Warburg effect by downregulating ACTG1 in hepatocellular carcinoma

Yingcai Yan1,2,*
Hao Xu1,2,*
Linshi Zhang1,2
Xiaohu Zhou1,2
Xiaohui Qian1,2
Jiarong Zhou1,2
Yu Huang1,2
Wenhao Ge1,2
Weilin Wang1–4

1Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China; 2Key Laboratory of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Tumor of Zhejiang Province, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China; 3Clinical Research Center of Hepatobiliary and Pancreatic Diseases of Zhejiang Province, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China; 4State Key Laboratory and Collaborative Innovation Center for Diagnosis and Treatment of Infectious Disease, Zhejiang University, Hangzhou, China

*These authors contributed equally to this work

Purpose: Hepatocellular carcinoma (HCC) is a common malignancy with poor prognosis and limited therapeutic options. Ras-related associated with diabetes (RRAD) belongs to the subfamily of Ras-related GTPases and is associated with several types of cancer, including HCC, although the mechanisms involving RRAD in HCC remains unknown.

Patients and methods: We aimed to elucidate the role of RRAD and whether it affects glucose metabolism in HCC by immunohistochemically examining tissue samples from HCC patients and assessing the effect of RRAD overexpression and knockdown on the glucose metabolism, proliferation, cell cycle, and apoptosis of HCC cell lines SK-Hep-1 and Huh7, as well as on tumor progression in vivo.

Results: We demonstrated that RRAD binds to actin gamma 1 (ACTG1). RRAD suppressed aerobic glycolysis in HCC by downregulating ACTG1. On the other hand, ACTG1 promoted HCC proliferation by regulating the cell cycle via downregulation of cyclins and cyclin-dependent kinases and inhibited apoptosis through the mitochondrial apoptosis pathway in vitro. In addition, RRAD retarded tumor growth by downregulating ACTG1 in vivo. ACTG1 was overexpressed in HCC tissues compared with adjacent normal tissues, whereas the expression of RRAD was low in tumor tissues. Low RRAD levels were significantly correlated with large tumor size and advanced tumor stage; high ACTG1 levels were significantly correlated with advanced tumor stage. Furthermore, Kaplan–Meier survival curves showed that HCC patients with high RRAD and low ACTG1 expression may have a better prognosis.

Conclusion: We have shown that RRAD exhibits a tumor-suppressing role in HCC by downregulating glucose metabolism and ACTG1 expression, thus lowering cell proliferation, arresting the cell cycle, and increasing apoptosis. These findings indicate that ACTG1 may act as a downstream effector of RRAD and open a new avenue for potential HCC treatment.

Keywords: hepatocellular carcinoma, Ras-related associated with diabetes, actin gamma 1, the Warburg effect, tumorigenicity

Introduction

Hepatocellular carcinoma (HCC) is a frequently occurring malignancy with poor prognosis, whose mortality rate ranks second among cancer-related deaths.1 With average survival rates between 6 and 20 months, a better knowledge of the pathogenic mechanisms of HCC is urgently required to develop novel strategies for treating the disease.2,3

Under normal circumstances, cells depend upon mitochondrial oxidative phosphorylation, while cancer cells prefer aerobic glycolysis, also known as the Warburg effect.4 Therefore, metabolic reprogramming must play a vital role in the biobehavioral
mechanism of cancer. Increased glucose uptake levels and lactate production have been linked to tumor progression, and recent studies have revealed that oncogene activation and/or tumor suppressor gene mutations are related to increased glycolysis.

Ras-related associated with diabetes (RRAD), which belongs to the 35–39 kDa class of the subfamily of Ras-related GTPases, was first identified in type II diabetes patients because of its abnormally high expression. We have previously shown that RRAD is linked to proliferation, apoptosis, and the Warburg effect in HCC cells. However, the exact mechanism that involves RRAD in HCC remains unknown.

In the present study, RRAD was found to play a critical role in the negative regulation of glycolysis through the induction of actin gamma 1 (ACTG1), which belongs to γ-actins, a class of proteins existing in most cell types as components of the cytoskeleton. ACTG1 is reportedly related to conditions such as hearing loss, while a more recent study implicated that ACTG1 overexpression could improve the proliferation and clone formation of skin cancer cells. However, the biological functions of ACTG1 in HCC have not been studied yet.

In our study, we demonstrated that RRAD binds to ACTG1. Knockdown of ACTG1 in HCC cell lines likely reduces cell proliferation and the Warburg effect and promotes apoptosis, while overexpression of ACTG1 has the opposite effect. Moreover, ACTG1 is upregulated in HCC cells, while its high expression in tumor tissues may be related to a poorer prognosis. Therefore, our results reveal a significant role of and mechanism by which RRAD may regulate the Warburg effect in HCC, thus contributing to its tumor-suppressing role.

Patients and methods

Patient data, tissue samples, and immunohistochemistry

Ninety HCC tumor samples and corresponding peri-tumor tissues were obtained from patients who underwent HCC resection in our department between 2014 and 2016. The patients had no liver-related comorbidities and did not receive any preoperative therapy. The tissues were conserved at −80°C until further analysis. Clinical data were collected and assessed by two independent physicians. The study was approved by the Human Research Ethics Committee of The First Affiliated Hospital, College of Medicine, Zhejiang University. Written informed consent was obtained from all patients. We confirmed that this was conducted in accordance with the Declaration of Helsinki.

Anti-RRAD rabbit polyclonal antibody (ab75100; Abcam, Cambridge, UK) and anti-ACTG1 mouse monoclonal antibody (ab123034; Abcam) were used as the primary antibodies for immunohistochemical staining; the staining was performed as described previously. All slides were examined by two pathologists, who were blinded to clinical patient data.

Cell culture

The HCC cell lines Huh7 and SK-Hep-1 were purchased from ATCC (https://www.atcc.org/) commercially and cultured in DMEM (Thermo Fisher Scientific, Waltham, MA, USA), with 10% heat-inactivated FBS (Sigma-Aldrich Co., St Louis, MO, USA). All cells were maintained in an incubator containing 95% air and 5% CO₂ at 37°C.

Cell transfection

RRAD siRNAs, together with negative controls (NCs), were synthesized by GenePharma (Shanghai, China) and used to transfect the SK-Hep-1 cells at a concentration of 10 nM. The siRNA sequences were as follows: NC, 5′-UUCUCCGAACGUGACACGU-3′ and antisense 5′-ACGUGACACGUUCGGAGAATT-3′; and si-RRAD, 5′-GACUCAGACGAGCGUUUTT-3′ and antisense 5′-AAACGCUCUCUGACUGUCUTT-3′. The cells were treated as described previously. Adenoviruses overexpressing RRAD, NC/P53, or NC and replication-defective lentiviruses encoding RRAD, NC/AKTG1, or NC were constructed by Genechem. ACTG1-specific shRNA-expressing (sh-ACTG1) lentiviruses were produced by Sigma-Aldrich Co. (TRCN0000029478) using the sequence “CCGCGCATCTCTCTTCTCTGGACTCGAGTCC AGAGAGAGAGTCCGT TTT”. The cells were treated as described previously.

Western blotting

Western blotting was performed as described previously. GAPDH was stained (anti-GAPDH [60004-1-lg]; Proteintech, Rosemount, IL, USA) and used for normalization. Primary antibodies against RRAD, ACTG1, P53, HIS, GST, cyclin A2, cyclin D1, cyclin E1, CDK2, CDK4, caspase-3, PARP, BAX, GLUT1, LDHA, FBPI, and PKM2 (Abcam) were used.

Glucose uptake, lactate production assay, and extracellular acidification rate measurement

Glucose uptake was measured using 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose (Thermo
Fisher Scientific) as described previously. Lactate production was measured by Lactate Colorimetric Assay Kit II (BioVision, Milpitas, CA, USA). For extracellular acidification rate (ECAR) measurement, the Extracellular Flux Analyzer and XF Glycolysis Stress kit (Seahorse Bioscience, North Billerica, MA, USA) were used.

**Co-immunoprecipitation (Co-IP) assays and LC-MS/MS analysis**

Co-IP assays were performed as described previously. To detect the potential RRAD-binding proteins, GST-RRAD protein was pulled down by IP using anti-GST beads. Analysis was performed using liquid chromatography–tandem mass spectrometry (LC-MS/MS; Ekspert NanoLC and TripleTOF 5600+; Sciex, Framingham, MA, USA).

**Cell proliferation and cell cycle analysis**

Cell Counting Kit-8 (Dojindo Laboratories, Kumamoto, Japan) and EdU assay (Cell-Light™ EdU Apollo567 In Vitro Imaging Kit; Ribobio, Guangzhou, China) were used for cell proliferation analysis. Flow cytometry (Cytomics FC 500; Beckman Coulter, Miami, FL, USA) was used for cell cycle analysis, as described previously.

**Cell apoptosis assay**

Forty-eight hours after transfection, the cells were harvested and double stained with 5 μL of annexin V-fluorescein isothiocyanate and 5 μL of propidium iodide in the dark for 30 minutes. Apoptosis distribution was then detected by flow cytometry.

**Subcutaneous tumor growth**

All experimental animal procedures were performed according to the institutional ethical requirements and were approved by the Zhejiang Medical Experimental Animal Care Commission. Cells and mice were treated as described previously, and corresponding data were recorded. The tumor volume was calculated using the following formula: volume = L × W²/2, where L and W are the longest and shortest diameters of the tumors, respectively.

**Statistical analyses**

Data were analyzed using SPSS software (version 24; IBM Corporation, Armonk, NY, USA). Figures were drawn using GraphPad Prism software (version 6.0; GraphPad, San Diego, CA, USA). The results were expressed as mean values ± SD from three independent experiments. Differences were considered statistically significant for P-values < 0.05, using Student’s t-test.

**Results**

**RRAD suppresses the Warburg effect in HCC cells**

Recently, it has been shown that the viability of cancer cells is linked to glucose levels and lactate levels in the extracellular milieu. To evaluate whether RRAD plays a role in the regulation of glucose metabolism, we silenced RRAD in SK-Hep-1 cells using siRNA and transfected Huh7 cells with an RRAD-overexpressing lentivirus. Effective knockdown and overexpression of RRAD was confirmed (Figure 1G and H). Two hallmarks of glycolysis, glucose uptake and lactate production, were measured, and both were significantly enhanced in SK-Hep-1 cells (Figure 1A and C) and decreased in Huh7 cells (Figure 1B and D). Moreover, real-time ECAR measurement and the glycolysis stress assays were used to determine various parameters of glycolytic capacity of the cells. These showed that knockdown of RRAD in SK-Hep-1 cells with increased ECAR (Figure 1E), while overexpression of RRAD in Huh7 cells decreased ECAR (Figure 1F).

In order to determine the underlying mechanism that results in the inhibition of the Warburg effect, we detected relative protein levels. The results indicated that glucose transporter 1 (GLUT1) was upregulated when RRAD was
knocked down, while GLUT1 levels were lower when RRAD was overexpressed. There was no significant difference in the levels of other proteins (Figure 1G and H).

RRAD binds to ACTG1 and is regulated by P53
To further study the mechanism by which RRAD represses the Warburg effect, STRING was used to predict the proteins that interact with RRAD. We found that P53 may be linked to RRAD (Figure 2A). We then transfected Huh7 cells with RRAD- and P53-overexpressing adenoviruses and found that RRAD expression was significantly upregulated when P53 was overexpressed, while there was no significant difference in P53 expression when RRAD was overexpressed (Figure 2B). Using Co-IP and LC-MS/MS assays to further explore the potential proteins that RRAD interacts with

**Figure 1** RRAD regulates aerobic glycolysis in HCC cells.
**Notes:** (A, B) Glucose uptake was enhanced/decreased when RRAD was knocked down/overexpressed. (C, D) Lactate production was enhanced/decreased when RRAD was knocked down/overexpressed. (E, F) ECAR was enhanced/decreased when RRAD was knocked down/overexpressed. (G, H)Expression of GLUT1 was upregulated/downregulated when RRAD was knocked down/overexpressed. Other proteins showed no significance. *P < 0.05, **P < 0.01, ***P < 0.005.

**Abbreviations:** RRAD, Ras-related associated with diabetes; ECAR, extracellular acidification rate; HCC, hepatocellular carcinoma; GLUT1, glucose transporter 1; NC, negative control.
(Figure 2C) and glutathione-S-transferase (GST) pull-down assays to obtain more accurate results, we confirmed that RRAD interacts with ACTG1 (Figure 2D).

**ACTG1 is associated with HCC cell proliferation, cell cycle, and apoptosis**

Next, we aimed to determine the effect of ACTG1 expression on HCC cells. The CCK-8 assay showed that ACTG1 overexpression in SK-Hep-1 cells and knockdown in Huh7 cells increased and decreased the viability of the cells, respectively (Figure 3A and B), which was in accordance with the results of the EdU assay (Figure 3C and D).

After silencing ACTG1, we observed an increase in the percentage of cells in G1-phase and a reduction in S-phase cells compared with the NC cells (Figure 3F). In addition, this resulted in decreased expression of cyclin A2, cyclin D1, cyclin E1, CDK2, and CDK4 (Figure 3G). As expected, ACTG1 overexpression in SK-Hep-1 cells had the opposite effect (Figure 3E and G).

In addition, overexpression of ACTG1 decreased apoptosis (Figure 4A), whereas its knockdown increased apoptosis (Figure 4B), both effects being accompanied by a corresponding alteration in the levels of the apoptosis-related proteins BAX, cleaved caspase-3, and PARP (Figure 4C).

**ACTG1 promotes the Warburg effect in vitro**

Glucose uptake, lactate production, and ECAR measurements showed that overexpression of ACTG1 improved glucose uptake, lactate production, and ECAR (Figure 5A, C and E) along with the upregulation of GLUT1 (Figure 5G). Contrastingly, knockdown of ACTG1 reduced these parameters (Figure 5B, D, F and H).

**ACTG1 acts as a functional downstream effector of RRAD in HCC cells**

To investigate whether the tumor-suppressing role of RRAD in HCC cells is mediated by inhibiting the expression of ACTG1, SK-Hep-1 cells were co-transfected with lentiviruses encoding RRAD and ACTG1; RRAD-induced ACTG1 downregulation was rescued following the co-transfection (Figure 6F). Moreover, the inhibitory role of RRAD in glucose
Figure 3 Effect of ACTG1 on the proliferation and cell cycle of HCC cells.

Notes: (A, B) Cell viability was enhanced/decreased when ACTG1 was overexpressed/knocked down. (C, D) EdU assays showed that cell proliferation was enhanced/decreased when ACTG1 was overexpressed/knocked down. Arrows indicate cells with high viability. All the cells can be identified by Hoechst in blue and cells with high viability can be identified by EdU in red. Cells with high viability are pink when merged. (E, F) Cell cycle analysis for SK-Hep-1 cells treated with NC or ACTG1 lentivirus/Huh7 cells transfected with NC or ACTG1 shRNAs. (G) Expression of cyclin A2/D1/E1 and CDK2/4 was upregulated/downregulated when ACTG1 was overexpressed/knocked down. *p<0.05, **p<0.005.

Abbreviations: HCC, hepatocellular carcinoma; ACTG1, actin gamma 1; NC, negative control.
uptake, lactate production, ECAR, and cell proliferation was reverted when ACTG1 was overexpressed (Figure 6A–D), while the rate of apoptosis was reduced (Figure 6E). The mRNA level of ACTG1 was downregulated when RRAD was overexpressed (Figure 6F). The relative protein levels changed correspondingly (Figure 6G).

**Overexpression of RRAD suppressed tumor progression through ACTG1 in vivo**

To confirm the tumor-suppressing role of RRAD in vivo, a subcutaneous xenograft model was constructed. SK-Hep-1 cells transfected with RRAD− and RRAD+
Figure 5 ACTG1 influences aerobic glycolysis in HCC cells.

Notes: (A, B) Glucose uptake was enhanced/decreased when ACTG1 was overexpressed/knocked down. (C, D) Lactate production was enhanced/decreased when ACTG1 was overexpressed/knocked down. (E, F) Extracellular acidification rate (ECAR) was enhanced/decreased when ACTG1 was overexpressed/knocked down. (G, H) Expression of GLUT1 was upregulated/downregulated when ACTG1 was overexpressed/knocked down. Other proteins showed no significance. *P<0.05, **P<0.01, ***P<0.005.

Abbreviations: HCC, hepatocellular carcinoma; ACTG1, actin gamma 1; NC, negative control; GLUT1, glucose transporter 1.
Figure 6 ACTG1 acts as a functional downstream effector of RRAD in HCC cells.

Notes: (A–E) Glucose uptake assay/lactate production assay/extracellular acidification rate (ECAR) measurement/CCK-8 assay/apoptosis assay in SK-Hep-1 cells transfected with NC/RRAD lentivirus and co-transfected with lentiviruses encoding the RRAD and ACTG1. (F) The mRNA level of ACTG1 was downregulated when RRAD was overexpressed. (G) Expression of proteins related to cell cycle/apoptosis/aerobic glycolysis in SK-Hep-1 cells by Western blotting. **P<0.01, ***P<0.005.

Abbreviations: HCC, hepatocellular carcinoma; ACTG1, actin gamma 1; NC, negative control; RRAD, Ras-related associated with diabetes; CCK, cell counting kit.
ACTG1-overexpression lentiviruses, as well as NC cells, were injected into nude mice. In accordance with the in vitro results, the tumors in the mice injected with RRAD-overexpressing cells were obviously smaller, which could be rescued by ACTG1 overexpression (Figure 7A–C). To further investigate the effect of RRAD on HCC in vivo, we performed an immunohistochemistry assay on the tumor removed from nude mice. The expression of GLUT1 was

![Image](https://www.dovepress.com/)

**Figure 7** RRAD inhibits tumor growth through ACTG1 in vivo and RRAD/AKTG1 is associated with prognosis of patients.

**Notes:** (A) Tumors removed from nude mice (n=5 biological replicates). (B, C) Mean tumor weight/volume showed that the tumor from the lv-RRAD cells were smaller, and could be rescued by ACTG1 (**P<0.01, ***P<0.001). (D) Expression of GLUT1, RRAD, and ACTG1 in tumor removed from nude mice. Magnification ×200. (E, F) Survival analysis of HCC patients by Kaplan–Meier plots and log-rank tests. Patients were categorized by high and low expression of RRAD/AKTG1. (G) Survival analysis of HCC patients by Kaplan–Meier plots and log-rank tests (four groups): high RRAD and high ACTG1; high RRAD and low ACTG1; low RRAD and high ACTG1; low RRAD and low ACTG1.

**Abbreviations:** HCC, hepatocellular carcinoma; ACTG1, actin gamma 1; NC, negative control; RRAD, Ras-related associated with diabetes; GLUT1, glucose transporter 1.
higher in the NC group, and the downregulation of GLUT1 induced by the overexpression of RRAD can be rescued by ACTG1 overexpression, which implied that inhibition of tumor growth by RRAD is related to suppression of the Warburg effect (Figure 7D).

**Expression of RRAD is low when ACTG1 is overexpressed in HCC tumor specimens and is linked to poor prognosis**

Expression of RRAD in tumor tissues was lower, while ACTG1 expression was higher, than in the corresponding peri-tumor tissues in the 90-patient cohort. In addition, low expression of RRAD was significantly correlated with increased tumor size and advanced tumor stages (Table 1), and high expression of ACTG1 was significantly correlated with advanced tumor stages (Table 2). Low RRAD expression was associated with poor prognosis according to the Kaplan–Meier survival curves, while high ACTG1 expression was correlated with poor prognosis in patients with HCC (Figure 7E and F). Taken together, these indicate that patients with high levels of RRAD and low levels of ACTG1 may have a better prognosis (Figure 7G).

**Table 1** Correlation between RRAD expression and the statistical analyses of the clinicopathological features of the patients were performed by Pearson’s chi-squared test

<table>
<thead>
<tr>
<th>Variables</th>
<th>Low-RRAD</th>
<th>High-RRAD</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>In general</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adjacent tissue</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tumor tissue</td>
<td>48</td>
<td>42</td>
<td></td>
</tr>
<tr>
<td>Sex</td>
<td>0.397</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>39</td>
<td>31</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>9</td>
<td>11</td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td>0.401</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤50</td>
<td>14</td>
<td>9</td>
<td></td>
</tr>
<tr>
<td>&gt;50</td>
<td>34</td>
<td>33</td>
<td></td>
</tr>
<tr>
<td>Tumor size (cm)</td>
<td>&lt;0.001</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤5</td>
<td>11</td>
<td>25</td>
<td></td>
</tr>
<tr>
<td>&gt;5</td>
<td>37</td>
<td>17</td>
<td></td>
</tr>
<tr>
<td>TNM stage</td>
<td>&lt;0.001</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I–II</td>
<td>20</td>
<td>37</td>
<td></td>
</tr>
<tr>
<td>III–IV</td>
<td>28</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>Tumor differentiation</td>
<td>0.083</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I–II</td>
<td>27</td>
<td>31</td>
<td></td>
</tr>
<tr>
<td>III–IV</td>
<td>21</td>
<td>11</td>
<td></td>
</tr>
</tbody>
</table>

**Table 2** Correlation between ACTG1 expression and the statistical analyses of the clinicopathological features of the patients were performed by Pearson’s chi-squared test

<table>
<thead>
<tr>
<th>Variables</th>
<th>Low-ACTG1</th>
<th>High-ACTG1</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>In general</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adjacent tissue</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tumor tissue</td>
<td>27</td>
<td>63</td>
<td></td>
</tr>
<tr>
<td>Sex</td>
<td>0.470</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>21</td>
<td>53</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>6</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td>0.411</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤50</td>
<td>11</td>
<td>20</td>
<td></td>
</tr>
<tr>
<td>&gt;50</td>
<td>16</td>
<td>43</td>
<td></td>
</tr>
<tr>
<td>Tumor size (cm)</td>
<td>0.104</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤5</td>
<td>12</td>
<td>17</td>
<td></td>
</tr>
<tr>
<td>&gt;5</td>
<td>15</td>
<td>46</td>
<td></td>
</tr>
<tr>
<td>TNM stage</td>
<td>0.001</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I–II</td>
<td>16</td>
<td>14</td>
<td></td>
</tr>
<tr>
<td>III–IV</td>
<td>11</td>
<td>49</td>
<td></td>
</tr>
<tr>
<td>Tumor differentiation</td>
<td>0.069</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I–II</td>
<td>10</td>
<td>12</td>
<td></td>
</tr>
<tr>
<td>III–IV</td>
<td>17</td>
<td>51</td>
<td></td>
</tr>
</tbody>
</table>

**Note:** Bold values represent P<0.05.

**Abbreviation:** RRAD, Ras-related associated with diabetes.

**Discussion**

Understanding the Warburg effect is of importance because it is specific to cancer cells, wherein it is employed to meet their energy and biosynthesis demands. We have previously demonstrated that RRAD plays a role in the negative regulation of cell proliferation, cell migration, and the Warburg effect in HCC cells. As was one of the first members of 35-39KD class of novel Ras-related GTPases, RRAD is connected with skeletal muscle β-tropomyosin. However, the exact mechanism of how it suppresses the tumorigenicity of HCC remains unknown.

In the present study, we used STRING to predict the proteins that interact with RRAD. We found that P53 may be linked to RRAD and RRAD may act as a downstream factor of P53. Next, we used Co-IP and LC-MS/MS assays to screen for the potential proteins that interact with RRAD. Using the GST pull-down assay, we identified ACTG1 as an important RRAD-binding protein. ACTG1 belongs to the family of actins, which participate in a variety of cellular activities, including in cell viability and cell shape maintenance and phagocytosis. ACTG1 is essential for the stability of hair cell stereocilia, while its mutations may cause deafness or
on the Baraitser-Winter syndrome. A recent study revealed the oncogenic effect of ACTG1 in skin cancer, wherein its overexpression may lead to cancer cell proliferation and migration. However, the role of ACTG1 in HCC has not been previously reported.

Here, we showed that ACTG1 plays a crucial role in HCC. Namely, its expression was higher in HCC tissues than in the corresponding peri-tumor tissues, and this was significantly correlated to advanced tumor stages. On the other hand, the expression of RRAD was low in HCC tissues, and this was significantly correlated to large tumor size and advanced tumor stage. These findings indicate that HCC patients with high RRAD and low ACTG1 levels may have a better prognosis.

Furthermore, we demonstrated that ACTG1 has a tumor-promoting function, that is, it improved HCC cell proliferation, while its knockdown led to G1 phase arrest and downregulation of the levels of cyclins A2, D1, and E1 and CDK2 and CDK4, proteins associated with the cell cycle. Since binding of cyclin A or E to CDK2 facilitates G1/S transition and the cyclin D/CDK4 complex inactivates retinoblastoma proteins and leads to E2F-dependent transcription advancement, the effect of ACTG1 on HCC cell proliferation likely occurred via the upregulation of cyclins and CDKs.

In addition, as reduced apoptosis is associated with tumor development, we tested the effect of ACTG1 on the major effectors of the intrinsic and extrinsic apoptosis pathways in HCC cells. The rate of apoptosis in HCC cells, accompanied by the expression of BAX, cleaved caspase-3, and PARP, increased when ACTG1 was knocked down, while ACTG1 overexpression had the opposite effect, indicating that ACTG1 may indeed contribute to HCC development by inhibiting the intrinsic apoptosis pathway.

Finally, we have shown that RRAD is linked to glucose metabolism in HCC cells by downregulating GLUT1, which initiates glycolysis by increasing glucose import into the cytoplasm. The results indicated that ACTG1 may promote the Warburg effect by upregulating the expression of GLUT1 in HCC cells. However, whether the tumor-suppressing role of RRAD in HCC cells is achieved via the inhibition of ACTG1 expression remains to be revealed. Herein, we found that RRAD-induced ACTG1 downregulation was rescued following co-transfection, and the inhibitory role of RRAD in glucose uptake, lactate production, ECAR, and cell proliferation was reverted when ACTG1 was overexpressed, indicating that ACTG1 may act as a functional downstream effector of RRAD in HCC cells. These findings may open a new avenue for potential HCC treatment.

**Conclusion**

Our study shows for the first time that RRAD binds to ACTG1. RRAD suppressed the Warburg effect in HCC cells by downregulating ACTG1. ACTG1 promoted HCC proliferation by regulating the cell cycle and suppressing the apoptosis of HCC cells in vitro. In addition, RRAD retarded tumor growth by downregulating ACTG1 in vivo. ACTG1 was overexpressed in HCC tissues compared with corresponding peri-tumor tissues, whereas the expression of RRAD was lower in tumor tissues. The low expression of RRAD was significantly correlated to large tumor size and advanced tumor stage and high expression of ACTG1 was significantly correlated to advanced tumor stage, indicating that patients with high RRAD and low ACTG1 levels may have a better prognosis. These results identify ACTG1 as a new oncogene and enrich the recessive oncogenic role of RRAD in HCC, which may provide new methods for cancer therapy.

**Acknowledgment**

This work was supported by The National Natural Science Foundation of China (No 81572307, 81773096) and Major Project of Medical and Health Technology Development Program in Zhejiang Province (Nos 7211902, 2016KYB083, LGD19C040006).

**Disclosure**

The authors report no conflicts of interest in this work.

**References**